Safety of systemic therapy for noninfectious uveitis

References

• Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica. 2004;218(4):223–236.
   PubMed Web of Science ®Google Scholar
• Trusko B, Thorne J, Jabs D, et al. The standardization of uveitis nomenclature (SUN) project. Development of a clinical evidence base utilizing informatics tools and techniques. Methods Inf Med. 2013;52(3):259–65, S1-6.
   PubMed Web of Science ®Google Scholar
• Lee K, Bajwa A, Freitas-Neto CA, et al. A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I. Expert Opin Pharmacother. 2014;15(15):2141–2154.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Venerito V, Sota J, et al. Epidemiological profile of non-infectious uveitis from the rheumatologist’s perspective: a survey from two tertiary referral centres in Italy. Clin Exp Rheumatol. 2018;36(6 Suppl 115):68–73.
   PubMed Web of Science ®Google Scholar
• Barry RJ, Nguyen QD, Lee RW, et al. Pharmacotherapy for uveitis: current management and emerging therapy. Clin Ophthalmol. 2014;8:1891–1911.
   PubMedGoogle Scholar
• Sadiq MA, Agarwal A, Hassan M, et al. Therapies in development for non-infectious uveitis. Curr Mol Med. 2015;15(6):565–577.
   PubMed Web of Science ®Google Scholar
• Depla JA, Van Calster J. Serpiginous choroiditis treated in a stepladder approach. Bull Soc Belge Ophtalmol. 2007;306:9–13.
   Google Scholar
• Lee FF, Foster CS. Pharmacotherapy of uveitis. Expert Opin Pharmacother. 2010;11(7):1135–1146.
   PubMed Web of Science ®Google Scholar
• Wegmann TG, Lin H, Guilbert L, et al. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today. 1993;14(7):353–356.
   PubMedGoogle Scholar
• Agarwal RK, Chan CC, Wiggert B, et al. Pregnancy ameliorates induction and expression of experimental autoimmune uveitis. J Immunol. 1999;162(5):2648–2654.
   PubMed Web of Science ®Google Scholar
• Dudich E. MM-093, a recombinant human alpha-fetoprotein for the potential treatment of rheumatoid arthritis and other autoimmune diseases. Curr Opin Mol Ther. 2007;9(6):603–610.
   PubMedGoogle Scholar
• Elenkov IJ, Wilder RL, Bakalov VK, et al. IL-12, TNF-alpha, and hormonal changes during late pregnancy and early postpartum: implications for autoimmune disease activity during these times. J Clin Endocrinol Metab. 2001;86(10):4933–4938.
   PubMed Web of Science ®Google Scholar
• Grotting LA, Papaliodis GN. A review of the course and treatment of non-infectious uveitis during pregnancy. Semin Ophthalmol. 2017;32(1):75–81.
   PubMed Web of Science ®Google Scholar
• Granner DK, Wang JC, Yamamoto KR. Regulatory actions of glucocorticoid hormones: from organisms to mechanisms. Adv Exp Med Biol. 2015;872:3–31.
   PubMed Web of Science ®Google Scholar
• Peckett AJ, Wright DC, Riddell MC. The effects of glucocorticoids on adipose tissue lipid metabolism. Metabolism. 2011;60(11):1500–1510.
   PubMed Web of Science ®Google Scholar
• Shen Y, Roh HC, Kumari M, et al. Adipocyte glucocorticoid receptor is important in lipolysis and insulin resistance due to exogenous steroids, but not insulin resistance caused by high fat feeding. Mol Metab. 2017;6(10):1150–1160.
   PubMed Web of Science ®Google Scholar
• Liu XX, Zhu XM, Miao Q, et al. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab. 2014;65(4):324–332.
   PubMed Web of Science ®Google Scholar
• Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol. 2000;16(4):505–511.
   PubMed Web of Science ®Google Scholar
• Meng X, Chen X, Wu L, et al. The hyperlipidemia caused by overuse of glucocorticoid after liver transplantation and the immune adjustment strategy. J Immunol Res. 2017;2017:3149426.
   PubMed Web of Science ®Google Scholar
• Anagnostis P, Athyros VG, Tziomalos K, et al. Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. J Clin Endocrinol Metab. 2009;94(8):2692–2701.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Burmester GR, Lipworth BJ. Inflammation, glucocorticoids and risk of cardiovascular disease. Nat Clin Pract Rheumatol. 2009;5(1):18–19.
   Google Scholar
• Walker BR. Glucocorticoids and cardiovascular disease. Eur J Endocrinol. 2007;157(5):545–559.
   PubMed Web of Science ®Google Scholar
• Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141(10):764–770.
   PubMed Web of Science ®Google Scholar
• Coelho MC, Santos CV, Vieira Neto L, et al. Adverse effects of glucocorticoids: coagulopathy. Eur J Endocrinol. 2015;173(4):M11–21.
   PubMed Web of Science ®Google Scholar
• Berthon BS, MacDonald-Wicks LK, Wood LG. A systematic review of the effect of oral glucocorticoids on energy intake, appetite, and body weight in humans. Nutr Res. 2014;34(3):179–190.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Kumar A. Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options. Clin Cornerstone. 2009;9(4):55–68. discussion 9-71.
   PubMedGoogle Scholar
• Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11(6):954–963.
   PubMedGoogle Scholar
• Caplan A, Fett N, Rosenbach M, et al. Prevention and management of glucocorticoid-induced side effects: a comprehensive review: infectious complications and vaccination recommendations. J Am Acad Dermatol. 2017;76(2):191–198.
   PubMed Web of Science ®Google Scholar
• Herrou J, De Lastours V. Predictive factors of pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis. 2018. Epub ahead of print.
   PubMed Web of Science ®Google Scholar
• Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236(6):619–632.
   PubMed Web of Science ®Google Scholar
• Frenkel B, White W, Tuckermann J. Glucocorticoid-induced osteoporosis. Adv Exp Med Biol. 2015;872:179–215.
   PubMed Web of Science ®Google Scholar
• Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis. N Engl J Med. 2018;379(26):2547–2556.
   PubMed Web of Science ®Google Scholar
• Allen CS, Yeung JH, Vandermeer B, et al. Bisphosphonates for steroid-induced osteoporosis. Cochrane Database Syst Rev. 2016;10:CD001347.
   PubMedGoogle Scholar
• West S, Kenedi C. Strategies to prevent the neuropsychiatric side-effects of corticosteroids: a case report and review of the literature. Curr Opin Organ Transplant. 2014;19(2):201–208.
   PubMed Web of Science ®Google Scholar
• Carli L, Tani C, Querci F, et al. Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists’ practice for the monitoring of glucocorticoid eye toxicity. Clin Rheumatol. 2013;32(7):1071–1073.
   PubMed Web of Science ®Google Scholar
• Ferrante P, Ramsey A, Bunce C, et al. Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin Exp Ophthalmol. 2004;32(6):563–568.
   PubMed Web of Science ®Google Scholar
• Kok H, Lau C, Maycock N, et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112(11):1916 e1–7.
   Web of Science ®Google Scholar
• Sallam A, Taylor SR, Habot-Wilner Z, et al. Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema. Acta Ophthalmol. 2012;90(4):e323–5.
   PubMed Web of Science ®Google Scholar
• Lowder C, Belfort R Jr., Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545–553.
   PubMed Web of Science ®Google Scholar
• Tomkins-Netzer O, Taylor SR, Bar A, et al. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology. 2014;121(8):1649–1654.
   PubMed Web of Science ®Google Scholar
• Writing Committee for the Multicenter Uveitis Steroid Treatment T, Follow-up Study Research G, Kempen JH, Altaweel MM, Holbrook JT, et al. Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA 2017;317(19):1993–2005.
   PubMed Web of Science ®Google Scholar
• Thorne JE, Sugar EA, Holbrook JT, et al. Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology. 2019;126(2):283–295.
   PubMed Web of Science ®Google Scholar
• Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol. 1999;128(1):63–68.
   PubMed Web of Science ®Google Scholar
• Carvalho-Recchia CA, Yannuzzi LA, Negrao S, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002;109(10):1834–1837.
   PubMed Web of Science ®Google Scholar
• Nicholson BP, Atchison E, Idris AA, et al. Central serous chorioretinopathy and glucocorticoids: an update on evidence for association. Surv Ophthalmol. 2018;63(1):1–8.
   PubMed Web of Science ®Google Scholar
• Imasawa M, Ohshiro T, Gotoh T, et al. Central serous chorioretinopathy following vitrectomy with intravitreal triamcinolone acetonide for diabetic macular oedema. Acta Ophthalmol Scand. 2005;83(1):132–133.
   PubMedGoogle Scholar
• Kocabora MS, Durmaz S, Kandemir N. Exacerbation of central serous chorioretinopathy following intravitreal triamcinolone injection. Graefes Arch Clin Exp Ophthalmol. 2008;246(12):1783–1786.
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kamppeter BA. Intravitreal triamcinolone acetonide and central serous chorioretinopathy. Br J Ophthalmol. 2005;89(3):386–387.
   PubMed Web of Science ®Google Scholar
• Bowie EM, Folk JC, Barnes CH. Corticosteroids, central serous chorioretinopathy, and neurocysticercosis. Arch Ophthalmol. 2004;122(2):281–283.
   PubMedGoogle Scholar
• Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385–392.
   PubMedGoogle Scholar
• Bandoli G, Palmsten K, Forbess Smith CJ, et al. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin North Am. 2017;43(3):489–502.
   PubMed Web of Science ®Google Scholar
• Ali A, Rosenbaum JT. Use of methotrexate in patients with uveitis. Clin Exp Rheumatol. 2010;28(5 Suppl 61):S145–50.
   PubMed Web of Science ®Google Scholar
• Howard SC, McCormick J, Pui CH, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471–1482.
   PubMed Web of Science ®Google Scholar
• Hassan M, Karkhur S, Bae J, et al. New therapies in development for the management of non-infectious uveitis: a review. Clin Exp Ophthalmol. 2019;47:396–417.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review. Eur J Med Chem. 2018;158:502–516.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Beukelman T, Onofrei A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. Ann Rheum Dis. 2010;69(01):43–47.
   PubMed Web of Science ®Google Scholar
• Attar SM. Adverse effects of low dose methotrexate in rheumatoid arthritis patients. A hospital-based study. Saudi Med J. 2010;31(8):909–915.
   PubMed Web of Science ®Google Scholar
• Bressolle F, Bologna C, Kinowski JM, et al. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann Rheum Dis. 1998;57(2):110–113.
   PubMed Web of Science ®Google Scholar
• Mori S, Hidaka M, Kawakita T, et al. Factors associated with myelosuppression related to low-dose methotrexate therapy for inflammatory rheumatic diseases. PloS One. 2016;11(4):e0154744.
   PubMed Web of Science ®Google Scholar
• Ostensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006;8(3):209.
   PubMed Web of Science ®Google Scholar
• Johns DG, Rutherford LD, Leighton PC, et al. Secretion of methotrexate into human milk. Am J Obstet Gynecol. 1972;112(7):978–980.
   PubMed Web of Science ®Google Scholar
• Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148(4):500–9.e2.
   PubMed Web of Science ®Google Scholar
• Fuggle NR, Bragoli W, Mahto A, et al. The adverse effect profile of oral azathioprine in pediatric atopic dermatitis, and recommendations for monitoring. J Am Acad Dermatol. 2015;72(1):108–114.
   PubMed Web of Science ®Google Scholar
• Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial. Lancet. 2006;367(9513):839–846.
   PubMed Web of Science ®Google Scholar
• Berth-Jones J, Takwale A, Tan E, et al. Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial. Br J Dermatol. 2002;147(2):324–330.
   PubMed Web of Science ®Google Scholar
• Al Rifai A, Prasad N, Shuttleworth E, et al. Natural history of azathioprine-associated lymphopenia in inflammatory bowel disease patients: a prospective observational study. Eur J Gastroenterol Hepatol. 2011;23(2):153–158.
   PubMed Web of Science ®Google Scholar
• Steponaitiene R, Kupcinskas J, Survilaite S, et al. TPMT and ITPA genetic variants in Lithuanian inflammatory bowel disease patients: prevalence and azathioprine-related side effects. Adv Med Sci. 2016;61(1):135–140.
   PubMed Web of Science ®Google Scholar
• Polifka JE, Friedman JM. Teratogen update: azathioprine and 6-mercaptopurine. Teratology. 2002;65(5):240–261.
   PubMedGoogle Scholar
• Akbari M, Shah S, Velayos FS, et al. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(1):15–22.
   PubMed Web of Science ®Google Scholar
• Singh M, Qualie J, Currie A, et al. Is breastfeeding safe with azathioprine? Obstet Med. 2011;4(3):104–107.
   PubMedGoogle Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47(2–3):85–118.
   PubMed Web of Science ®Google Scholar
• Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(3):423–32.e1-2.
   PubMed Web of Science ®Google Scholar
• Thorne JE, Jabs DA, Qazi FA, et al. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology. 2005;112(8):1472–1477.
   PubMed Web of Science ®Google Scholar
• Omair MA, Alahmadi A, Johnson SR. Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review. PLoS One. 2015;10(5):e0124205.
   PubMed Web of Science ®Google Scholar
• Rathinam SR, Babu M, Thundikandy R, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology. 2014;121(10):1863–1870.
   PubMed Web of Science ®Google Scholar
• Hoeltzenbein M, Elefant E, Vial T, et al. Teratogenicity of mycophenolate confirmed in a prospective study of the European network of teratology information services. Am J Med Genet A. 2012;158A(3):588–596.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513.
   PubMed Web of Science ®Google Scholar
• Ishioka M, Ohno S, Nakamura S, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol. 1994;118(6):723–729.
   PubMed Web of Science ®Google Scholar
• Mochizuki M, Masuda K, Sakane T, et al. A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol. 1993;115(6):763–769.
   PubMed Web of Science ®Google Scholar
• Kilmartin DJ, Forrester JV, Dick AD. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol. 1998;82(7):737–742.
   PubMed Web of Science ®Google Scholar
• Walton RC, Nussenblatt RB, Whitcup SM. Cyclosporine therapy for severe sight-threatening uveitis in children and adolescents. Ophthalmology. 1998;105(11):2028–2034.
   PubMed Web of Science ®Google Scholar
• Mathews D, Mathews J, Jones NP. Low-dose cyclosporine treatment for sight-threatening uveitis: efficacy, toxicity, and tolerance. Indian J Ophthalmol. 2010;58(1):55–58.
   PubMed Web of Science ®Google Scholar
• Kacmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117(3):576–584.
   PubMed Web of Science ®Google Scholar
• Larson T, Nussenblatt RB, Sen HN. Emerging drugs for uveitis. Expert Opin Emerg Drugs. 2011;16(2):309–322.
   PubMed Web of Science ®Google Scholar
• Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet’s disease. Lancet. 1989;1(8647):1093–1096.
   PubMed Web of Science ®Google Scholar
• BenEzra D, Cohen E, Chajek T, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet’s syndrome. Transplant Proc. 1988;20(3 Suppl 4):136–143.
   PubMed Web of Science ®Google Scholar
• Hesselink DA, Baarsma GS, Kuijpers RW, et al. Experience with cyclosporine in endogenous uveitis posterior. Transplant Proc. 2004;36(2Suppl):372S–7S.
   PubMed Web of Science ®Google Scholar
• Isnard Bagnis C, Tezenas Du Montcel S, Beaufils H, et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol. 2002;13(12):2962–2968.
   PubMed Web of Science ®Google Scholar
• Burdmann EA, Andoh TF, Yu L, et al. Cyclosporine nephrotoxicity. Semin Nephrol. 2003;23(5):465–476.
   PubMed Web of Science ®Google Scholar
• Palestine AG, Austin HA 3rd, Balow JE, et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med. 1986;314(20):1293–1298.
   PubMed Web of Science ®Google Scholar
• Shalaby U. Diltiazem co treatment with cyclosporine for induction of disease remission in sight-threatening non-infectious intraocular inflammation. Jpn J Ophthalmol. 2017;61(2):169–178.
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Koneru B, Wang CC, et al. Cyclosporine and its metabolites in mother and baby. Transplantation. 1988;46(3):468–469.
   PubMed Web of Science ®Google Scholar
• Nandakumaran M, Eldeen AS. Transfer of cyclosporine in the perfused human placenta. Dev Pharmacol Ther. 1990;15(2):101–105.
   PubMedGoogle Scholar
• Flechner SM, Katz AR, Rogers AJ, et al. The presence of cyclosporine in body tissues and fluids during pregnancy. Am J Kidney Dis. 1985;5(1):60–63.
   PubMed Web of Science ®Google Scholar
• Oz B B, Hackman R, Einarson T, et al. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001;71(8):1051–1055.
   PubMed Web of Science ®Google Scholar
• Moretti ME, Sgro M, Johnson DW, et al. Cyclosporine excretion into breast milk. Transplantation. 2003;75(12):2144–2146.
   PubMed Web of Science ®Google Scholar
• Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology. 1999;106(4):723–728.
   PubMed Web of Science ®Google Scholar
• Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol. 2005;123(5):634–641.
   PubMedGoogle Scholar
• Webster AC, Woodroffe RC, Taylor RS, et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ. 2005;331(7520):810.
   PubMed Web of Science ®Google Scholar
• Kitahara K, Kawai S. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2007;19(3):238–245.
   PubMed Web of Science ®Google Scholar
• Islam F, Westcott M, Rees A, et al. Safety profile and efficacy of tacrolimus in the treatment of birdshot retinochoroiditis: a retrospective case series review. Br J Ophthalmol. 2018;102(7):983–990.
   PubMed Web of Science ®Google Scholar
• Hogan AC, McAvoy CE, Dick AD, et al. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology. 2007;114(5):1000–1006.
   PubMed Web of Science ®Google Scholar
• Kainz A, Harabacz I, Cowlrick IS, et al. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation. 2000;70(12):1718–1721.
   PubMed Web of Science ®Google Scholar
• Gardiner SJ, Begg EJ. Breastfeeding during tacrolimus therapy. Obstet Gynecol. 2006;107(2 Pt 2):453–455.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Glassock RJ. Prevention of complications from use of conventional immunosuppressants: a critical review. J Nephrol. 2019;32:851–870.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2001;131(5):679.
   PubMed Web of Science ®Google Scholar
• Fauci AS, Haynes BF, Katz P, et al. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med. 1983;98(1):76–85.
   PubMed Web of Science ®Google Scholar
• Queisi MM, Zein M, Lamba N, et al. Update on ocular cicatricial pemphigoid and emerging treatments. Surv Ophthalmol. 2016;61(3):314–317.
   PubMed Web of Science ®Google Scholar
• Buckley CE 3rd, Gills JP Jr. Cyclophosphamide therapy of peripheral uveitis. Arch Intern Med. 1969;124(1):29–35.
   PubMed Web of Science ®Google Scholar
• Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010;117(2):356–365.
   PubMed Web of Science ®Google Scholar
• Fain O, Du LTH, Wechsler B. Pulse cyclophosphamide in Behçet’s disease. O’Duffy JD, Kokmen, E., editor. New York: Marcel Dekker; 1991.
   Google Scholar
• Esterberg E, Acharya NR. Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect. 2012;2(1):21–28.
   PubMedGoogle Scholar
• Olivieri I, Leccese P, D’Angelo S, et al. Efficacy of adalimumab in patients with Behcet’s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S54–7.
   PubMed Web of Science ®Google Scholar
• Foster CS. Systemic immunosuppressive therapy for progressive bilateral Mooren’s ulcer. Ophthalmology. 1985;92(10):1436–1439.
   PubMed Web of Science ®Google Scholar
• Tateishi M, Taniguchi A, Moriguchi M, et al. [Cyclophosphamide pulse therapy for refractory rheumatic diseases]. Nihon Rinsho Meneki Gakkai Kaishi. 1997;20(3):152–158.
   PubMedGoogle Scholar
• Monach PA, Arnold LM, Merkel PA. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review. Arthritis Rheum. 2010;62(1):9–21.
   PubMed Web of Science ®Google Scholar
• King C, Harper L. Avoidance of harm from treatment for ANCA-associated vasculitis. Curr Treatm Opt Rheumatol. 2017;3(4):230–243.
   PubMedGoogle Scholar
• Faurschou M, Sorensen IJ, Mellemkjaer L, et al. Malignancies in Wegener’s granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol. 2008;35(1):100–105.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ. 2009;339:b2480.
   PubMedGoogle Scholar
• Enns GM, Roeder E, Chan RT, et al. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? Am J Med Genet. 1999;86(3):237–241.
   PubMed Web of Science ®Google Scholar
• Fierro ME, Datta P, Rewers-Felkins K, et al. Cyclophosphamide use in multiple sclerosis: levels detected in human milk. Breastfeed Med. 2019;14(2):128–130.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Duncan JH. Cyclophosphamide in human milk. Lancet. 1971;1(7705):912.
   PubMed Web of Science ®Google Scholar
• O’Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet’s disease. Am J Med. 1984;76(1):75–84.
   PubMed Web of Science ®Google Scholar
• Tricoulis D. Treatment of Behcet’s disease with chlorambucil. Br J Ophthalmol. 1976;60(1):55–57.
   PubMed Web of Science ®Google Scholar
• Kanski JJ. Anterior uveitis in juvenile rheumatoid arthritis. Arch Ophthalmol. 1977;95(10):1794–1797.
   PubMedGoogle Scholar
• Godfrey WA, Epstein WV, O’Connor GR, et al. The use of chlorambucil in intractable idiopathic uveitis. Am J Ophthalmol. 1974;78(3):415–428.
   PubMed Web of Science ®Google Scholar
• Jennings T, Tessler HH. Twenty cases of sympathetic ophthalmia. Br J Ophthalmol. 1989;73(2):140–145.
   PubMed Web of Science ®Google Scholar
• Mudun BA, Ergen A, Ipcioglu SU, et al. Short-term chlorambucil for refractory uveitis in Behcet’s disease. Ocul Immunol Inflamm. 2001;9(4):219–229.
   PubMed Web of Science ®Google Scholar
• Shotton D, Monie IW. Possible teratogenic effect of chlorambucil on a human fetus. JAMA. 1963;186:74–75.
   PubMed Web of Science ®Google Scholar
• Leslie KK, Koil C, Rayburn WF. Chemotherapeutic drugs in pregnancy. Obstet Gynecol Clin North Am. 2005;32(4):627–640.
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Moroni G. Fetal toxicity of immunosuppressive drugs in pregnancy. J Clin Med. 2018;7:12.
   Web of Science ®Google Scholar
• Moudgil KD, Choubey D. Cytokines in autoimmunity: role in induction, regulation, and treatment. J Interferon Cytokine Res. 2011;31(10):695–703.
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN. Lasker clinical medical research award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med. 2003;9(10):1245–1250.
   PubMed Web of Science ®Google Scholar
• Gardner PJ, Yazid S, Chu CJ, et al. TNFalpha regulates SIRT1 cleavage during ocular autoimmune disease. Am J Pathol. 2015;185(5):1324–1333.
   PubMed Web of Science ®Google Scholar
• Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 2003;14(3–4):185–191.
   PubMed Web of Science ®Google Scholar
• Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol. 2002;20(6 Suppl 28):S152–7.
   PubMed Web of Science ®Google Scholar
• Minozzi S, Bonovas S, Lytras T, et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin Drug Saf. 2016;15(sup1):11–34.
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–1104.
   PubMed Web of Science ®Google Scholar
• Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol. 2008;35(3):421–424.
   PubMed Web of Science ®Google Scholar
• Ferri C, Ferraccioli G, Ferrari D, et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol. 2008;35(10):1944–1949.
   PubMed Web of Science ®Google Scholar
• Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–283.
   PubMed Web of Science ®Google Scholar
• Vigano M, Degasperi E, Aghemo A, et al. Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management. Expert Opin Biol Ther. 2012;12(2):193–207.
   PubMed Web of Science ®Google Scholar
• Barone M, Notarnicola A, Lopalco G, et al. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology. 2015;62(1):40–46.
   PubMed Web of Science ®Google Scholar
• Magnano MD, Robinson WH, Genovese MC. Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol. 2004;22(5 Suppl 35):S134–40.
   PubMed Web of Science ®Google Scholar
• Solomon AJ, Spain RI, Kruer MC, et al. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult Scler. 2011;17(12):1472–1487.
   PubMed Web of Science ®Google Scholar
• Simsek I, Erdem H, Pay S, et al. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis. 2007;66(9):1255–1258.
   PubMed Web of Science ®Google Scholar
• Chang V, McCurdy D, Gordon LK. Etanercept associated optic neuropathy. Clin Exp Ophthalmol. 2007;35(7):680–682.
   PubMed Web of Science ®Google Scholar
• Chan JW, Castellanos A. Infliximab and anterior optic neuropathy: case report and review of the literature. Graefes Arch Clin Exp Ophthalmol. 2010;248(2):283–287.
   PubMed Web of Science ®Google Scholar
• von Jagow B, Kohnen T. Anterior optic neuropathy associated with adalimumab. Ophthalmologica. 2008;222(4):292–294.
   PubMed Web of Science ®Google Scholar
• Balakumar P, Singh M. Anti-tumour necrosis factor-alpha therapy in heart failure: future directions. Basic Clin Pharmacol Toxicol. 2006;99(6):391–397.
   PubMed Web of Science ®Google Scholar
• Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010;62(8):2517–2524.
   PubMed Web of Science ®Google Scholar
• Shelton E, Laharie D, Scott FI, et al. Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2016;151(1):97–109 e4.
   PubMed Web of Science ®Google Scholar
• Shovman O, Tamar S, Amital H, et al. Diverse patterns of anti-TNF-alpha-induced lupus: case series and review of the literature. Clin Rheumatol. 2018;37(2):563–568.
   PubMed Web of Science ®Google Scholar
• Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford). 2009;48(7):716–720.
   PubMed Web of Science ®Google Scholar
• Debandt M, Vittecoq O, Descamps V, et al. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol. 2003;22(1):56–61.
   PubMed Web of Science ®Google Scholar
• Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford). 2011;50(8):1445–1452.
   PubMed Web of Science ®Google Scholar
• Hashkes PJ, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol. 2003;21(5):645–646.
   PubMed Web of Science ®Google Scholar
• Daien CI, Monnier A, Claudepierre P, et al. Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology (Oxford). 2009;48(8):883–886.
   PubMed Web of Science ®Google Scholar
• Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat. 2009;20(2):100–108.
   PubMed Web of Science ®Google Scholar
• Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 2001;44(6):1411–1415.
   PubMed Web of Science ®Google Scholar
• Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121(4):437–440.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123(7):903–912.
   PubMedGoogle Scholar
• Wendling D, Paccou J, Berthelot JM, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41(3):503–510.
   PubMed Web of Science ®Google Scholar
• Diaz-Llopis M, Garcia-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther. 2008;24(3):351–361.
   PubMed Web of Science ®Google Scholar
• Hoxha A, Calligaro A, Di Poi E, et al. Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: a prospective multicentre study. Joint Bone Spine. 2017;84(2):169–173.
   PubMed Web of Science ®Google Scholar
• Kane S. Trick or TREAT? More safety data of infliximab during pregnancy. Am J Gastroenterol. 2018;113(11):1592–1593.
   PubMed Web of Science ®Google Scholar
• Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007;56(6):830–837.
   PubMed Web of Science ®Google Scholar
• Weber-Schoendorfer C, Oppermann M, Wacker E, et al. network of French pharmacovigilance c, Beghin D, et al. Pregnancy outcome after TNF-alpha inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015;80(4):727–739.
   PubMed Web of Science ®Google Scholar
• O’Donnell S, O’Morain C. Review article: use of antitumour necrosis factor therapy in inflammatory bowel disease during pregnancy and conception. Aliment Pharmacol Ther. 2008;27(10):885–894.
   PubMed Web of Science ®Google Scholar
• Fritzsche J, Pilch A, Mury D, et al. Infliximab and adalimumab use during breastfeeding. J Clin Gastroenterol. 2012;46(8):718–719.
   PubMed Web of Science ®Google Scholar
• Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J Gastroenterol. 2008;14(19):3085–3087.
   PubMed Web of Science ®Google Scholar
• Scott DL. Etanercept in arthritis. Int J Clin Pract. 2005;59(1):114–118.
   PubMed Web of Science ®Google Scholar
• Markomichelakis N, Delicha E, Masselos S, et al. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet’s disease: a comparative 4-week study. Rheumatology (Oxford). 2011;50(3):593–597.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, St Clair EW, McCune WJ, et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2000;27(4):841–850.
   PubMed Web of Science ®Google Scholar
• Artornsombudh P, Gevorgyan O, Payal A, et al. Infliximab treatment of patients with birdshot retinochoroidopathy. Ophthalmology. 2013;120(3):588–592.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Christensen R, Bang D, et al. Update of the EULAR recommendations for the management of Behcet’s syndrome. Ann Rheum Dis. 2018;77(6):808–818.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol. 2009;127(6):819–822.
   PubMed Web of Science ®Google Scholar
• Lamireau T, Cezard JP, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn’s disease. Inflamm Bowel Dis. 2004;10(6):745–750.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376(17):1637–1646.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943.
   PubMed Web of Science ®Google Scholar
• Hamam RN, Barikian AW, Antonios RS, et al. Intravitreal adalimumab in active noninfectious uveitis: a pilot study. Ocul Immunol Inflamm. 2016;24(3):319–326.
   PubMed Web of Science ®Google Scholar
• Kheir WJ, Mehanna CJ, Abdul Fattah M, et al. Intravitreal adalimumab for the control of breakthrough intraocular inflammation. Ocul Immunol Inflamm. 2018;26(8):1206–1211.
   PubMed Web of Science ®Google Scholar
• Steeples LR, Spry P, Lee RWJ, et al. Adalimumab in refractory cystoid macular edema associated with birdshot chorioretinopathy. Int Ophthalmol. 2018;38(3):1357–1362.
   PubMed Web of Science ®Google Scholar
• Marin J, Acosta Felquer ML, Soriano ER. Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy. Open Access Rheumatol. 2018;10:33–41.
   PubMed Web of Science ®Google Scholar
• Llorenc V, Mesquida M, Sainz de la Maza M, et al. Certolizumab Pegol, a new anti-TNF-alpha in the armamentarium against ocular inflammation. Ocul Immunol Inflamm. 2016;24(2):167–172.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Hayashi T, Takahashi G, et al. Successful certolizumab pegol treatment of chronic anterior uveitis associated with psoriasis vulgaris. Case Rep Ophthalmol. 2018;9(3):499–503.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Emmi G, Gentileschi S, et al. Certolizumab Pegol treatment in Behcet’s disease with different organ involvement: a multicenter retrospective observational study. Mod Rheumatol. 2017;27(6):1031–1035.
   PubMed Web of Science ®Google Scholar
• Tosi GM, Sota J, Vitale A, et al. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clin Exp Rheumatol. 2019;37(4):680–683.
   PubMed Web of Science ®Google Scholar
• Shealy DJ, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs. 2010;2(4):428–439.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Sota J, Rigante D, et al. Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Behcet’s disease. Ocul Immunol Inflamm. 2019;27(1):58–63.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Doyle M, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor alpha inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study. Arthritis Res Ther. 2015;17:14.
   PubMed Web of Science ®Google Scholar
• Calvo-Rio V, Blanco R, Santos-Gomez M, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum. 2016;46(1):95–101.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Pontikaki I, et al. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2014;22(2):90–95.
   PubMed Web of Science ®Google Scholar
• Achieving clinical response and remission in moderate-to-severe ulcerative colitis with Golimumab. Gastroenterol Hepatol. 2014;10(7):452–454.
   Google Scholar
• Kishimoto T. Interleukin-6: from basic science to medicine–40 years in immunology. Annu Rev Immunol. 2005;23:1–21.
   PubMed Web of Science ®Google Scholar
• Kishimoto T. The biology of interleukin-6. Blood. 1989;74(1):1–10.
   PubMed Web of Science ®Google Scholar
• Petrinovic-Doresic J, Mazuran R, Henc-Petrinovic L, et al. Interleukin 6 and its soluble receptor are elevated in aqueous humor of patients with uveitis. Ocul Immunol Inflamm. 1999;7(2):75–84.
   PubMed Web of Science ®Google Scholar
• Sheppard M, Laskou F, Stapleton PP, et al. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017;13(9):1972–1988.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371(9617):987–997.
   PubMed Web of Science ®Google Scholar
• Papo M, Bielefeld P, Vallet H, et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S75–9.
   PubMed Web of Science ®Google Scholar
• Deuter CME, Zierhut M, Igney-Oertel A, et al. Tocilizumab in uveitic macular edema refractory to previous immunomodulatory treatment. Ocul Immunol Inflamm. 2017;25(2):215–220.
   PubMed Web of Science ®Google Scholar
• Silpa-Archa S, Oray M, Preble JM, et al. Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol. 2016;94(6):e400–6.
   PubMed Web of Science ®Google Scholar
• Sepah YJ, Sadiq MA, Chu DS, et al. Primary (Month-6) Outcomes of the STOP-Uveitis study: evaluating the safety, tolerability, and efficacy of Tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol. 2017;183:71–80.
   PubMed Web of Science ®Google Scholar
• Ramanan AV, Dick AD, Jones AP, et al. A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial). BMC Rheumatol. 2018;2:4.
   PubMedGoogle Scholar
• Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67(11):1516–1523.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol. 2010;20(3):222–232.
   PubMed Web of Science ®Google Scholar
• Shovman O, Shoenfeld Y, Langevitz P. Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature. Immunol Res. 2015;61(1–2):164–168.
   PubMed Web of Science ®Google Scholar
• Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817–2829.
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968–2980.
   PubMed Web of Science ®Google Scholar
• Nakamura I, Omata Y, Naito M, et al. Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis. J Rheumatol. 2009;36(2):459–460.
   PubMed Web of Science ®Google Scholar
• Xie F, Yun H, Bernatsky S, et al. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving Tofacitinib, Tocilizumab, or other biologic treatments. Arthritis Rheumatol. 2016;68(11):2612–2617.
   PubMed Web of Science ®Google Scholar
• Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13(5):R141.
   PubMed Web of Science ®Google Scholar
• Al-Shakarchi I, Gullick NJ, Scott DL. Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review. Patient Prefer Adherence. 2013;7:653–666.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol. 2014;41(1):15–23.
   PubMed Web of Science ®Google Scholar
• Hoeltzenbein M, Beck E, Rajwanshi R, et al. Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data. Semin Arthritis Rheum. 2016;46(2):238–245.
   PubMed Web of Science ®Google Scholar
• Hassan M, Karkhur S, Bae JH, et al. New therapies in development for the management of non-infectious uveitis: a review. Clin Exp Ophthalmol. 2019;47(3):396–417.
   PubMed Web of Science ®Google Scholar
• Raimondo MG, Biggioggero M, Crotti C, et al. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Devel Ther. 2017;11:1593–1603.
   PubMed Web of Science ®Google Scholar
• Emery P, Rondon J, Parrino J, et al. Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis. Oxford: Rheumatology; 2018.
   Google Scholar
• Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76(5):840–847.
   PubMed Web of Science ®Google Scholar
• Heissigerova J, Callanan D, de Smet MD, et al. Efficacy and safety of Sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN study. Ophthalmology. 2019;126(3):428–437.
   PubMed Web of Science ®Google Scholar
• Mansouri B, Richards L, Menter A. Treatment of two patients with generalized pustular psoriasis with the interleukin-1beta inhibitor gevokizumab. Br J Dermatol. 2015;173(1):239–241.
   PubMed Web of Science ®Google Scholar
• Gul A, Tugal-Tutkun I, Dinarello CA, et al. Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis. 2012;71(4):563–566.
   PubMed Web of Science ®Google Scholar
• Geiler J, McDermott MF. Gevokizumab, an anti-IL-1beta mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. Curr Opin Mol Ther. 2010;12(6):755–769.
   PubMedGoogle Scholar
• Tugal-Tutkun I, Pavesio C, De Cordoue A, et al. Use of Gevokizumab in patients with Behcet’s disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study. Ocul Immunol Inflamm. 2018;26(7):1023–1033.
   PubMed Web of Science ®Google Scholar
• Knickelbein JE, Tucker WR, Bhatt N, et al. Gevokizumab in the treatment of autoimmune non-necrotizing anterior Scleritis: results of a phase I/II clinical trial. Am J Ophthalmol. 2016;172:104–110.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Lopalco G, Caso F, et al. Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behcet’s disease. Autoimmun Rev. 2015;14(1):1–9.
   PubMed Web of Science ®Google Scholar
• Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003;35(3Suppl):7S–14S.
   PubMed Web of Science ®Google Scholar
• Napoli KL, Taylor PJ. From beach to bedside: history of the development of sirolimus. Ther Drug Monit. 2001;23(5):559–586.
   PubMed Web of Science ®Google Scholar
• Chiu MI, Katz H, Berlin V. RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci U S A. 1994;91(26):12574–12578.
   PubMed Web of Science ®Google Scholar
• Powell JD, Pollizzi KN, Heikamp EB, et al. Regulation of immune responses by mTOR. Annu Rev Immunol. 2012;30:39–68.
   PubMed Web of Science ®Google Scholar
• Chi H. Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol. 2012;12(5):325–338.
   PubMed Web of Science ®Google Scholar
• Aylett CH, Sauer E, Imseng S, et al. Architecture of human mTOR complex 1. Science. 2016;351(6268):48–52.
   PubMed Web of Science ®Google Scholar
• Shanmuganathan VA, Casely EM, Raj D, et al. The efficacy of sirolimus in the treatment of patients with refractory uveitis. Br J Ophthalmol. 2005;89(6):666–669.
   PubMed Web of Science ®Google Scholar
• Roberge FG, Xu D, Chan CC, et al. Treatment of autoimmune uveoretinitis in the rat with rapamycin, an inhibitor of lymphocyte growth factor signal transduction. Curr Eye Res. 1993;12(2):197–203.
   PubMed Web of Science ®Google Scholar
• Sen HN, Larson TA, Meleth AD, et al. Subconjunctival sirolimus for the treatment of chronic active anterior uveitis: results of a pilot trial. Am J Ophthalmol. 2012;153(6):1038–1042.
   PubMed Web of Science ®Google Scholar
• Douglas LC, Yi NY, Davis JL, et al. Ocular toxicity and distribution of subconjunctival and intravitreal rapamycin in horses. J Vet Pharmacol Ther. 2008;31(6):511–516.
   PubMed Web of Science ®Google Scholar
• Mudumba S, Bezwada P, Takanaga H, et al. Tolerability and pharmacokinetics of intravitreal sirolimus. J Ocul Pharmacol Ther. 2012;28(5):507–514.
   PubMed Web of Science ®Google Scholar
• Ibrahim MA, Sepah YJ, Watters A, et al. One-year outcomes of the SAVE study: sirolimus as a therapeutic approach for UVEitis. Transl Vis Sci Technol. 2015;4(2):4.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Sadiq MA, Soliman MK, et al. The effect of different dosing schedules of intravitreal Sirolimus, a mammalian target of Rapamycin (mTOR) inhibitor, in the treatment of non-infectious uveitis (An American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc. 2016;114:T3.
   PubMedGoogle Scholar
• Nguyen QD, Merrill PT, Clark WL, et al. Intravitreal Sirolimus for noninfectious uveitis: a phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA). Ophthalmology. 2016;123(11):2413–2423.
   PubMed Web of Science ®Google Scholar
• Lerman MA, Rabinovich CE. The future is now: biologics for non-infectious pediatric anterior uveitis. Paediatr Drugs. 2015;17(4):283–301.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Keystone EC, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(2):143–150.
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390–1400.
   PubMed Web of Science ®Google Scholar
• Conti F, Perricone C, Ceccarelli F, et al. Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: two sides of the same coin. Autoimmun Rev. 2010;9(11):716–720.
   PubMed Web of Science ®Google Scholar
• Stasi R, Stipa E, Del Poeta G, et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford). 2006;45(11):1432–1436.
   PubMed Web of Science ®Google Scholar
• Puechal X, Iudici M, Calich AL, et al. Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients. Oxford: Rheumatology; 2018.
   Google Scholar
• Hu Y, Nie H, Yu HH, et al. Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. Autoimmun Rev. 2019;18(5):542–548.
   PubMed Web of Science ®Google Scholar
• Caso F, Rigante D, Vitale A, et al. Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease. Clin Rheumatol. 2015;34(10):1817–1820.
   PubMed Web of Science ®Google Scholar
• You C, Ma L, AF L, et al. Rituximab induction and maintenance treatment in patients with Scleritis and Granulomatosis with Polyangiitis (Wegener’s). Ocul Immunol Inflamm. 2018;26(8):1166–1173.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G, Berchicci L, et al. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol. 2016;100(6):782–786.
   PubMed Web of Science ®Google Scholar
• Lasave AF, You C, Ma L, et al. Long-term outcomes of rituximab therapy in patients with noninfectious posterior uveitis refractory to conventional immunosuppressive therapy. Retina. 2018;38(2):395–402.
   PubMed Web of Science ®Google Scholar
• Miserocchi E, Modorati G. Rituximab for noninfectious uveitis. Dev Ophthalmol. 2012;51:98–109.
   PubMedGoogle Scholar
• Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68(1):25–32.
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis. 2008;67(Suppl 3):iii64–5.
   PubMed Web of Science ®Google Scholar
• Chakravarty EF, Murray ER, Kelman A, et al. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499–1506.
   PubMed Web of Science ®Google Scholar
• Namour F, Diderichsen PM, Cox E, et al. Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of Filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection. Clin Pharmacokinet. 2015;54(8):859–874.
   PubMed Web of Science ®Google Scholar
• Genovese M, Westhovens R, Meuleners L, et al. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes. Arthritis Res Ther. 2018;20(1):57.
   PubMed Web of Science ®Google Scholar
• D’Amico F, Fiorino G, Furfaro F, et al. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. Expert Opin Investig Drugs. 2018;27(7):595–599.
   PubMed Web of Science ®Google Scholar
• Perez-Jeldres T, Tyler CJ, Boyer JD, et al. Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists. Front Pharmacol. 2019;10:212.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10162):2378–2387.
   PubMed Web of Science ®Google Scholar
• Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392(10162):2367–2377.
   PubMed Web of Science ®Google Scholar